Uncategorized

XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

MGC Pharmaceuticals Ltd. announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter drug in the USA on the FDA National Drug Code Database under the code 83278.

Quince Therapeutics, Inc., a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital.

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA®.

POXEL SA announced that it will report its 2022 full year results by the end of March 2023.

RELIEF THERAPEUTICS Holding SA announces survey results identifying preferred urea cycle disorder treatment attributes from its collaboration partner ACER Therapeutics, Inc.

IRLAB Therapeutics AB announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders on Friday, March 31, 2023.

Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.

Chinese leading biopharmaceutical company 3SBio announced its 2022 annual results.

Mesoblast Limited announced that, as part of the ongoing review of the BLA for remestemcel-L in the treatment of children with SR-aGVHD, the United States Food and Drug Administration has scheduled a Pre-License Inspection of Mesoblast’s cell therapy manufacturing operations at Lonza Bioscience in Singapore.